Foot Locker Stock a...
Health Care: Drugs
AEterna Zentaris Inc. (AEZS: NASDAQ)
$1.88 -0.02 | -0.93%
06/19/13 - 11:13 AM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with AEZS
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- UserMillion Dollar Portfolio
- Userwright stocks
- UserSMITTY
- UserFiuza 1
- Userherb's portfolio
- Contributor10 Pharma Stocks Under $3
Latest AEZS Headlines from TheStreet
- 5 Stocks Under $10 Ready to Soar Higher 02.07.13 | 01:02 pm
- Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin 01.25.13 | 07:01 am
- 5 Biotech Stocks Rising on Unusual Volume 11.20.12 | 02:11 pm
- 5 Stocks Under $10 Set to Soar 09.20.12 | 01:09 pm
- Biotech Stock Mailbag: Navidea, Celsion, Raptor and Threshold 09.14.12 | 06:09 am
- 2012 Biotech Stock Predictions: An Interim Report Card 08.28.12 | 07:08 am
- ASCO '12 Stocks: Winners and Losers 06.04.12 | 06:06 am
- ASCO '12: Colon Cancer Drugs Good (Roche) and Very Bad (Keryx Pharma) 06.03.12 | 06:06 am
- Keryx: Lessons From a Drug Failure 04.02.12 | 12:04 pm
- AEterna Zentaris Stock Gaps Down On Today's Open (AEZS) 04.02.12 | 09:04 am
Press Releases for AEZS
- Aeterna Zentaris Announces Dismissal Of Class Action Lawsuit - PR Newswire 06.06.13 | 04:06 pm
- Aeterna Zentaris: Encouraging Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin (AEZS-108) In Prostate Cancer Reported At ASCO - PR Newswire 06.03.13 | 09:06 am
- Aeterna Zentaris Announces "At-the-Market" Issuance Program - PR Newswire 05.21.13 | 04:05 pm
- Aeterna Zentaris To Present At Upcoming Bloom Burton & Co. Healthcare Investor Conference In Toronto - PR Newswire 05.15.13 | 07:05 am
- Aeterna Zentaris To Announce First Quarter 2013 Financial And Operating Results On May 7, 2013 And Hold Annual Shareholders Meeting On May 8, 2013 - PR Newswire 05.01.13 | 07:05 am
- Aeterna Zentaris Newly Appointed CEO, David A. Dodd, To Host Introductory Analyst And Investor Conference Call On Thursday, April 25, 2013 - PR Newswire 04.23.13 | 04:04 pm
- Aeterna Zentaris Announces Transfer Of Manufacturing Rights Related To Cetrotide® To Merck KGaA - PR Newswire 04.17.13 | 07:04 am
- David A. Dodd Appointed President & Chief Executive Officer Of Aeterna Zentaris Inc. - PR Newswire 04.15.13 | 08:04 am
- Aeterna Zentaris Presents Encouraging Updated Data On Its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates At AACR Meeting - PR Newswire 04.10.13 | 04:04 pm
- Aeterna Zentaris And Ergomed Sign Co-Development And Profit Sharing Agreement For AEZS-108 In Endometrial Cancer - PR Newswire 04.10.13 | 07:04 am
Partner Headlines for AEZS
- 4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce - Seeking Alpha 11.20.12 | 09:11 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 11.05.12 | 09:11 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 11.01.12 | 09:11 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 10.19.12 | 09:10 am
- Aeterna Zentaris Announces Closing of $16.5 Million Public Offering of Common Shares and Warrants - Benzinga 10.17.12 | 09:10 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.16.12 | 09:10 am
- Pre-Market Most Active for Oct 12, 2012 : BAC, AMD, S, JPM, WFC, BCS, CLWR, ASML, NPSP, QQQ, SIRI, AEZS - NASDAQ 10.12.12 | 12:10 pm
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- Healthcare Biz Recap: Aeterna Zentaris Shares Surge, J&J Files with FDA - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
